Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy
The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the lev...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
29.07.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The at least one marker is selected from the group consisting of creatinine, urea, sodium, glucose, HbAlc (glycated hemoglobin), hemoglobin, and hematocrit. Further markers are disclosed. |
---|---|
Bibliography: | Application Number: EP20140152777 |